Polypeptide expressed in the horny layer of the epidermis and its use
Abstract
The present invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a purified natural or synthetic epidermis-specific polypeptide which is involved in horny layer cell cohesion. The invention also relates to a cosmetic or pharmaceutical composition comprising a mixture of polypeptides derived from the proteolysis of the purified polypeptide of the present invention. The present invention further relates to a method for strengthening horny layer cell cohesion which comprises applying the cosmetic or pharmaceutical composition of the present invention to the skin. Finally, the present invention relates to a method for reducing horny layer cell cohesion, and thereby promoting exfoliation, wherein said method comprises applying to the skin a cosmetic or pharmaceutical composition comprising an effective amount of at least one protease active on the polypeptide of the present invention.
Claims
exact text as granted — not AI-modified1 - 17 . (canceled)
18 . A cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, an effective quantity of at least one protease active on a polypeptide comprising Endoproteinase LysC, Endoproteinase GluC, Proline-Endopeptidase, Thrombin, Pepsin, Myxobacter AL117 and Elastase;
wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1.
19 . The composition according to claim 18 , further comprising, a glycosidase.
20 . A method for preventing or treating hyperkeratosis, comprising administering an effective amount of the composition according to claim 18 to a patient in need of such prevention or treatment.
21 . A method for preventing or treating xerosis, ichthyoses, psoriasis, benign or malignant hyperkeratotic tumour lesions or reactive keratoses, comprising administering an effective amount of the composition according to claim 18 to a patient in need of such prevention or treatment.
22 . A method for preventing or treating leukokeratosis of the uterine neck during prolapsus, buccal leukokeratoses, or benign or malignant hyperkeratotic tumour lesions of the Malpighian mucosae, comprising administering an effective amount of the composition according to claim 18 to a patient in need of such prevention or treatment.
23 . A method of cosmetic treatment for reducing intercorneocyte cohesion or for promoting desquamation, comprising administering an effective amount of the composition as described in claim 18 , wherein the composition is applied to the skin of the subject in need of such reduction or promotion.
24 . Cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least the following coding nucleotide sequence SEQ ID NO: 2:
1
ATG GGC TCG TCT CGG GCA CCC TGG ATG GGG CGT GTG GGT GGG CAC
46
GGG ATG ATG GCA CTG CTG CTG GCT GGT CTC CTC CTG CCA GGG ACC
91
TTG GCT AAG AGC ATT GGC ACC TTC TCA GAC CCC TGT AAG GAC CCC
136
ACG CGT ATC ACC TCC CCT AAC GAC CCC TGC CTC ACT GGG AAG GGT
181
GAC TCC AGC GGC TTC AGT AGC TAC AGT GGC TCC AGC AGT TCT GGC
226
AGC TCC ATT TCC AGT GCC AGA AGC TCT GGT GGT GGC TCC AGT GGT
271
AGC TCC AGC GGA TCC AGC ATT GCC CAG GGT GGT TCT GCA GGA TCT
316
TTT AAG CCA GGA ACG GGG TAT TCC CAG GTC AGC TAC TCC TCC GGA
361
TTT AAG CCA GGA ACG GGG TAT TCC CAG GTC AGC TAC TCC TCC GGA
406
AGC AGC AGC TCT CAC TCG GGA AGC AGC GGC TCT CAC TCG GGA AGC
451
AGC AGC TCT CAT TCG AGC AGC AGC AGC AGC TTT CAG TTC AGC AGC
496
AGC AGC TTC CAA GTA GGG AAT GGC TCT GCT CTG CCA ACC AAT GAC
541
AAC TCT TAC CGC GGA ATA CTA AAC CCT TCC CAG CCT GGA CAA AGC
586
TCT TCC TCT TCC CAA ACC TCT GGG GTA TCC AGC AGT GGC CAA AGC
631
GTC AGC TCC AAC CAG CGT CCC TGT AGT TCG GAC ATC CCC GAC TCT
676
CCC TGC AGT GGA GGG CCC ATC GTC TCG CAC TCT GGC CCC TAC ATC
721
CCC AGC TCC CAC TCT GTG TCA GGG GGT CAG AGG CCT GTG GTG GTG
766
GTG GTG GAC CAG CAC GGT TCT GGT GCC CCT GGA GTG GTT CAA GGT
811
CCC CCC TGT AGC AAT GGT GGC CTT CCA GGC AAG CCC TGT CCC CCA
856
ATC ACC TCT GTA GAC AAA TCC TAT GGT GGC TAC GAG GTG GTG GGT
901
GGC TCC TCT GAG AGT TAT CTG GTT CCA GGC ATG ACC TAC AGT AAG
946
GGT AAA ATC TAT CCT GTG GGC TAC TTC ACC AAA GAG AAC CCT GTG
991
AAA GGC TCT CCA GGG GTC CCT TCC TTT GCA GCT GGG CCC CCC ATC
1036
TCT GAG GGC AAA TAC TTC TCC AGC AAC CCC ATC ATC CCC AGC CAG
1081
TCG GCA GCT TCC TCG GCC ATT GCG TTC CAG CCA GTG GGG ACT GGT
1126
GGG GTC CAG CTC TGT GGA GGC GGC TCC ACG GGC TCC AAG GGA CCC
1171
TGC TCT CCC TCC AGT TCT CGA GTC CCC AGC AGT TCT AGC ATT TCC
1216
AGC AGC GCC GGT TCA CCC TAC CAT CCC TGC GGC AGT GCT TCC CAG
1261
AGC CCC TGC TCC CCA CCA GGC ACC GGC TCC TTC AGC AGC AGC TCC
1306
AGT TCC CAA TCG AGT GGC AAA ATC ATC CTT CAG CCT TGT GGC AGC
1351
AAG TCC AGC TCT TCT GGT CAC CCT TGC ATG TCT GTC TCC TCC TTG
1396
ACA CTG ACT GGG GGC CCC GAT GGC TCT CCC CAT CCT GAT CCC TCC
1441
GCT GGT GCC AAG CCC TGT GGC TCC AGC AGT GCT GGA AAG ATC CCC
1486
TGC CGC TCC ATC CGG GAT ATC CTA GCC CAA GTG AAG CCT CTG GGG
1531
CCC CAG CTA GCT GAC CCT GAA GTT TTC CTA CCC CAA GGA GAG TTA
1576
CTC GAC AGT CCA TAA
25 . The composition according to claim 24 , characterized in that the nucleotide sequence comprises all or part of the nucleotide sequence as described in claim 24 .
27 . (canceled)
28 . A method for the preparation of a ribonucleic acid, comprising using the nucleic acid sequence according to claim 24 .
29 . A method for preparing or purifying any molecule capable of binding specifically to a purified polypeptide or to purified proteolysis fragments or to a synthetic peptide;
wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1.
30 . A method for preparing or purifying structural proteins specific to corneodesmosomes or enzymes of the horny layer of the “protease” or “glycosidase” type, comprising using a composition comprising one or more purified natural or synthetic polypeptides, wherein each of the polypeptides comprises the amino acid sequence of SEQ ID NO:1.
31 . (canceled)Join the waitlist — get patent alerts
Track US2005112150A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.